Bubs management continues to run a tight ship, with no information leaking ahead of the upcoming qtrly update scheduled for release btwn Mon-We’d next week.
We’ve already delivered two consecutive qtrs of positive EBITDA, and all signs point to a third on the way.
How is MC still sitting around $100M? There are plenty of ASX 200 companies with billion-dollar valuations that are still burning cash and not yet EBITDA positive.
A rerate feels inevitable and overdue. Like Ord Minnett and others valuing Bubs at 20c or more, I believe this qtr could be the catalyst to finally unlock this fair valuation.
Here are some of Bubs last qtr achievements. - Positve EBITDA of $0.5m - net cash used in operating activities of $0.5m, compared to $12.2m in pcp - $17.2m in total cash and cash equivalents plus $5M in undrawn bank facilities - Gross margin of 50% vs. 49% in pcp - Bubs reaffirms FY25 outlook guidance of $102M - FDAdecision on permanent access is expected in October 2025 - USA revenue of $23.2m, up 28% on pcp - China revenue of $10.2m, up 45% on pcp - Rest of World revenue of $4.6m, up 85% on pcp
BUB Price at posting:
11.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)